698P A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB.
Authors
Ajani, JUdrea, A
Sarosiek, T
Shenker, M
Morgan, C
Pikiel, J
Wojcik, E
Swinson, D
Joseph, M
Luft, A
Salek, T
Tournigand, C
Ferry, D
Zhang, Y
Long, A
Kuo, W
Gao, L
Kauh, J
Mansoor, Was
Affiliation
Oncology, START Madrid-CIOCC, Madrid, SpainIssue Date
2017-09
Metadata
Show full item recordCitation
698P A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx369.082Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx369.082/4108785/698PA-doseresponse-study-of-ramucirumab-treatmentType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx369.082